In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MEETINGS - Medical fair "opinion exchange", mosan-EUROSALUTE 2000 (Italy) October 2000:

This article was originally published in Clinica

Executive Summary

The medical fair "opinion exchange", mosan-EUROSALUTE 2000, will be held at the Milan Trade fair, in Milan on October 11-14. Within the exhibiting area, institutions, research centres, industrial concerns, public and private health authorities, associations and European regions will be present. They will show the results of research, technological breakthroughs, and demonstrate application processes and tools. For more information contact the conference secretary. Tel: +39 02 481 5541. Fax: +39 02 4980330. Email: assoexpo@assoexpo.com www.assoexpo.com

You may also be interested in...



Executives On The Move: Eisai Taps Celgene And Sanofi VPs For Its Team, And Freeline Selects A CEO

Japanese big pharma Eisai taps Celgene and Sanofi execs as its new VPs for corporate affairs and market access. And Freeline Therapeutics, developer of gene therapies for bleeding disorders, selects a former Alnylam Pharma SVP as CEO.

Triptan Switches Offer Hope For Australia’s OTC Market

Switch expert Natalie Gauld says recent triptan switch recommendations signal a turnaround for Australia's OTC market.

Bharat Biotech Plans Coronavirus Vaccine

After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.

Topics

UsernamePublicRestriction

Register

MT076811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel